PHILADELPHIA, PA — Imvax, Inc., a clinical-stage biotechnology company, recently announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting. The event was held in Vancouver, British Columbia, Canada, from November 15-19, 2023.
The company presented new data from its Phase 1b study of IGV-001, a novel treatment for patients with newly diagnosed glioblastoma (ndGBM). Dr. Ian Y. Lee, Neurosurgeon at Henry Ford Health System, also shared insights about Imvax’s ongoing Phase 2b clinical trial of IGV-001 in patients with ndGBM.
“These presentations underscore the significance of the Phase 1b results to the IGV-001 program and reflect the rigor of the design of the ongoing Phase 2b trial,” said Dr. David W. Andrews, Chief Medical Officer of Imvax. He also expressed satisfaction with the progress of the Phase 2b study, which is enrolling well, with completion of enrollment expected in the first half of 2024.
The first poster presentation, “Additional results from a Phase 1b study of IGV-001 in patients with newly diagnosed glioblastoma,” revealed a statistically significant correlation in Imvax’s Phase 1b study of IGV-001 between progression-free survival (PFS) and overall survival (OS) in the intent-to-treat (ITT) study population. This finding suggests the use of median PFS as an end point in future ndGBM clinical trials. Additional data showed a significant decrease at various study points of the average neutrophil-to-lymphocyte (NLR) ratio, which may serve as a potential biomarker for positive clinical outcomes. This will be further investigated in Imvax’s ongoing Phase 2b study in ndGBM patients.
The second poster presentation, “A randomized, multicenter, double-blind, Phase 2b study of IGV-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients,” detailed the ongoing Phase 2b trial, including study objectives, design, endpoints, locations, and key inclusion and exclusion criteria.
These presentations at the SNO Annual Meeting underline Imvax’s commitment to advancing its IGV-001 program and its dedication to finding effective treatments for glioblastoma. As the company progresses with its Phase 2b trial, the medical community eagerly anticipates further updates.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.